Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

NCT00249002 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to pipeline prioritization

Conditions

Hemodialysis Graft Dysfunction

Interventions

DRUG: ABI-007

Sponsor

Celgene